Head-to-head dispatch
Claya vs Willow
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.
Marked down on: States-served list not disclosed — you must check at checkout
Desk Score
Telehealth provider offering compounded GLP-1 medications in both tablet and injectable formats.
Marked down on: Limited public information on program details
Claya takes this head-to-head with the higher Desk Score, 68/100 (C) against 65/100 (C) for Willow. Willow still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Claya
68/100
C
Willow
65/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Claya | Willow |
|---|---|---|
| Semaglutide | $299/mo (compounded) | $299/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (compounded) | $399/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name | Compounded only | Compounded only |
| Oral option | Yes | Yes |
| Best for | Readers who want compounded GLP-1 in injectable and oral-tablet forms with named clinicians. | Readers who want mainstream telehealth GLP-1 access. |
| Desk Score | 68/100C | 65/100C |
The verdict
Desk pick — ClayaClaya takes this head-to-head with the higher Desk Score, 68/100 (C) against 65/100 (C) for Willow. Willow still holds its ground where its strengths line up with yours.
Choose Claya if…
Readers who want compounded GLP-1 in injectable and oral-tablet forms with named clinicians.
$299/mo (compounded) sema · $299/mo (compounded) tirz · Coverage not published
Choose Willow if…
Readers who want mainstream telehealth GLP-1 access.
$299/mo (starting dose, compounded) sema · $399/mo (starting dose, compounded) tirz · Coverage not published
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Claya · Willow.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Claya vs CoreAge Rx
- Willow vs Vaylen
- Claya vs Strut Health
- Willow vs Ondra Health
- Claya vs Invigor Medical
- Willow vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.